Free Trial

Fennec Pharmaceuticals Inc. (TSE:FRX) Director Rostislav Christov Raykov Sells 10,000 Shares

Fennec Pharmaceuticals logo with Medical background

Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) Director Rostislav Christov Raykov sold 10,000 shares of the firm's stock in a transaction dated Thursday, July 3rd. The shares were sold at an average price of C$11.71, for a total transaction of C$117,096.00.

Rostislav Christov Raykov also recently made the following trade(s):

  • On Thursday, June 5th, Rostislav Christov Raykov sold 10,000 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of C$10.66, for a total transaction of C$106,586.00.
  • On Friday, May 16th, Rostislav Christov Raykov sold 16,667 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of C$9.49, for a total transaction of C$158,203.16.

Fennec Pharmaceuticals Stock Performance

Shares of FRX traded up C$0.27 on Friday, reaching C$12.16. The company's stock had a trading volume of 1,210 shares, compared to its average volume of 1,139. The company has a debt-to-equity ratio of -620.83, a current ratio of 7.80 and a quick ratio of 10.17. The stock has a market capitalization of C$234.50 million, a P/E ratio of -205.99 and a beta of 0.25. The stock's 50 day simple moving average is C$10.37 and its two-hundred day simple moving average is C$9.33. Fennec Pharmaceuticals Inc. has a 12-month low of C$5.65 and a 12-month high of C$12.16.

Fennec Pharmaceuticals Company Profile

(Get Free Report)

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.

Read More

Insider Buying and Selling by Quarter for Fennec Pharmaceuticals (TSE:FRX)

Should You Invest $1,000 in Fennec Pharmaceuticals Right Now?

Before you consider Fennec Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.

While Fennec Pharmaceuticals currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth
5 Stocks to BUY NOW in July 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines